The topics for discussion include:
- Patent legislation, both from the standpoint of a critical analysis of pending bills and whether other legislation may better reach the results sought;
- Section 101 patent eligibility after Bilski, Prometheus, and Myriad; the law of obviousness post KSR;
- De novo review of claim construction rulings;
- The implications of the Medtronic case now before the Supreme Court on patent licensing in the wake of Medimmune;
- The impact of the Federal Circuit’s decision in Fresenius v. Baxter on patent validity challenges; and
- The ITC’s domestic industry requirement; and proposed reform of appellate jurisdiction in patent cases.
People
Related Insights
13 September 2024
IP Litigation Current
Federal Circuit Says No Timing Requirement To Qualify As A POSITA
Share on TwitterShare by EmailShareBack to topLast week, in Osseo Imaging, LLC v. Planmeca USA Inc., No. 2023-1627 (Fed. Cir. Sept. 4, 2024)
September 24, 2024
Events
Do You Have AI Blind Spots in Your Licensing Agreements? Revisiting the Past, Considering the Present, and Planning for the Future
On Tuesday, September 24, Foley Partner Andrew Gross will speak on the panel “Do You Have AI Blind Spots in Your Licensing Agreements?
12 September 2024
Manufacturing Industry Advisor
Cybersecurity in the Age of Industry 4.0 – Part 1
As the manufacturing sector continues to embrace the hyper-connected era of Smart Manufacturing, known as Industry 4.0, more and more organizations are integrating advanced automation, artificial intelligence, the Internet of Things, and other cutting-edge innovations into their operations.